BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 2, 2026
Home » Topics » Clinical

Clinical
Clinical RSS Feed RSS

Silhouettes

Researchers ID new method to monitor schizophrenia drug in blood

March 4, 2021
By David Ho
HONG KONG – Researchers at Ben-Gurion University of the Negev (BGU) in Israel have developed a way to instantly monitor blood levels of the antipsychotic drug clozapine. BGU’s solution is based on an electrochemical microsensor developed by Hadar Ben-Yoav from BGU’s Department of Biomedical Engineering and Ilse Katz Institute for Nanoscale Science and Technology.
Read More
Cuba mask and syringe

Cuba’s Soberana 02 SARS-CoV-2 vaccine candidate moves to phase III trials

March 4, 2021
By Sergio Held
CAJICA, Colombia – Cuba’s Center for the State Control of Drugs, Equipment and Medical Devices gave the green light March 3 for phase III trials of a domestically developed COVID-19 vaccine candidate, even though very little peer-reviewed information has been published about it.
Read More

In the clinic for March 4, 2021

March 4, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Allarity, Apollomics, Cyclo, Dicerna, Diamyd, Dnatrix, Galapagos, Landos, Lilly, Mallinckrodt, Provention, Ridgeback, Roche, TFF, VBL, Ysopia.
Read More

In the clinic for March 3, 2021

March 3, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amgen, Arena, Azura, Bharat, Biomarin, Forendo, GSK, Incyte, Karolinska, Lilly, Longeveron, Maker, Morphosys, Ocugen, Prometheus, Reveragen, Santhera, Spectrum, Vir.
Read More

Ascletis joins Madrigal and Viking in global race for THR-β agonist for NASH

March 2, 2021
By Elise Mak
Liver disease specialist Ascletis Pharma Inc. said its nonalcoholic steatohepatitis (NASH)-focused subsidiary, Gannex Pharma Co. Ltd., will start global development of its oral THR-β agonist, ASC-41, after it obtained an IND approval from the FDA based on positive phase I data generated in China.
Read More
Silhouettes

Neurocrine schizophrenia thesis intact post-Interact? Opinions differ on phase II data

March 2, 2021
By Randy Osborne
San Diego-based Neurocrine Biosciences Inc.’s good-and-bad top-line phase II data with d-amino acid oxidase inhibitor luvadaxistat, also known NBI-1065844 and TAK-831, in schizophrenia likely came as little surprise to many, given earlier experience in the general pathway.
Read More

In the clinic for March 2, 2021

March 2, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aileron, Avadel, Biomx, Cerecor, Clearside, Gemoab, Highlight, Hoth, Inovio, Kymera, Eurocrine, Neurosense, NGM, Orbus, Pipeline, Scynexis, Seres.
Read More

In the clinic for March 1, 2021

March 1, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Accure, Algernon, Annexon, Aslan, Bioinvent, Innovent, Morphic, Ocular, Samsung Bioepis, Santhera, Satsuma, Takis, Transgene, VBL.
Read More
Illustration of digital syringe

Nference, Mayo Clinic study ties prior vaccinations to COVID-19 defense

Feb. 26, 2021
By Meg Bryant
A new study by Mayo Clinic and Nference Inc. researchers suggests that prior childhood and adult vaccinations for illnesses such as polio, measles and flu may provide protection against COVID-19 infection. The study, which analyzed patient data using Nference artificial intelligence (AI) software, underscores the critical role immunizations play in curbing the spread of diseases and preventing future pandemics. “What we discovered represents compelling evidence that vaccinations are a critical element in prevention of disease, even diseases one doesn’t anticipate,” said Venky Soundararajan, co-founder and chief scientific officer of the Cambridge, Mass.-based company.
Read More

Lack of clinical trial diversity could have consequences

Feb. 26, 2021
By Mari Serebrov
Drug and device companies dragging their feet on diversifying late-stage clinical trials could conceivably get a wake-up call in court or in FDA approval delays.
Read More
Previous 1 2 … 327 328 329 330 331 332 333 334 335 … 449 450 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 1, 2026.
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Illustration of antibodies and viral infection

    New evidence links autoimmunity to long COVID symptoms

    BioWorld
    Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
  • Liver with hepatitis viruses, blood cells

    Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

    BioWorld
    GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing